Compare DexCom, Inc. (DXCM) vs Forgent Power Solutions Inc. Class A Common Stock (FPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Forgent Power Solutions Inc. Class A Common Stock — how do they compare? DexCom, Inc. trades at $86.74 (market cap $31.51B), while Forgent Power Solutions Inc. Class A Common Stock trades at $31.2 (market cap $8.98B). The key difference: DexCom, Inc. is far larger — about 3.5× Forgent Power Solutions Inc. Class A Common Stock's market cap, and DexCom, Inc. is trading nearer its 52-week high, Forgent Power Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Forgent Power Solutions Inc. Class A Common Stock for 0 Days on average.
| DXCM | FPS | |
|---|---|---|
Market Cap | $31.51B | $8.98B |
Volume | 3,480,291 | 7,398,217 |
Sector | Health | Industrials |
52-Week High | $92.34 | $64.59 |
52-Week Low | $54.84 | $27.97 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $30.96B | $9.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $85.06, down 1.0% on the day, with a bullish technical signal and strong fundamental momentum. The stock is supported by consistent earnings beats, robust revenue growth from $4.0B in 2024 to $4.7B in 2025, and expanding net profit margins to 17.93%. Recent news highlights growth opportunities in Type 2 diabetes care and leadership appointments, reinforcing positive sentiment. Key resistance sits at $87, with immediate support at $85.
The outlook remains favorable given analyst consensus of a $96.14 price target and 80.77% buy ratings, though risks include competitive pressures and reimbursement challenges. Upside is driven by CGM adoption growth, while execution on guidance and market expansion are critical for sustained performance.
Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.
FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Forgent Power Solutions Inc. Class A Common Stock
Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.
Read more on FPS →
